Arrowhead Pharmaceuticals, Inc. (ARWR) vs Axsome Therapeutics, Inc. (AXSM)

Arrowhead Pharmaceuticals, Inc. and Axsome Therapeutics, Inc. are both Biotechnology companies. Axsome Therapeutics, Inc. is the larger, with a market value of $10.3B against $9.3B — 1.1× the size. Axsome Therapeutics, Inc. grew revenue faster over the last twelve months: 56.9% against 16.1%. Axsome Therapeutics, Inc. has the higher net margin (−24.7% vs −47.8%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Axsome Therapeutics, Inc. leads on 9 and Arrowhead Pharmaceuticals, Inc. on 7.

Valuation

Metric ARWR AXSM Biotechnology median
P/E n/m n/m 7.88
P/S 14.12 13.01 11.47
P/B 20.28 121.31 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 13.02 12.77 10.73
Earnings yield (3.41%) (1.92%) (28.84%)
Free cash flow yield (0.79%) (0.71%) (23.03%)

Profitability

Metric ARWR AXSM Biotechnology median
Gross margin 100.00% 93.24% 65.16%
Operating margin (33.82%) (23.96%) 0.00%
Net margin (47.79%) (24.68%) 0.00%
Free cash flow margin (11.22%) (9.27%) 0.00%
Return on equity (64.91%) (245.10%) (57.72%)
Return on assets (18.32%) (27.35%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ARWR AXSM Biotechnology median
Revenue growth (TTM) 16.13% 56.87% 5.64%
EPS growth (last fiscal year) 99.80% 38.56% —
Revenue growth, 5-year CAGR 56.63% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ARWR AXSM Biotechnology median
Debt to equity 1.85 1.52 0.00
Current ratio 5.90 1.43 4.73
Net debt to EBITDA (5.70) 1.29 0.96

Dividend

Metric ARWR AXSM Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ARWR AXSM Biotechnology median
Market cap 9.33b 10.27b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack